DUBLIN--(BUSINESS WIRE)--The "NHL:
Follicular Lymphoma Forecast and Market Analysis to 2025" drug
pipelines has been added to ResearchAndMarkets.com's
Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin's lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of all NHL cases. The disease is staged based on the percentage of large cells occurring within the malignant B lymphocytes. Low grades of FL are generally characterized by slow progression of the disease. Patients can be managed successfully to prolong remission times and extend survival, but the disease is mostly incurable. In contrast, higher grades of FL tend to become more aggressive in nature and require timely treatment.
Recent Events and Opinion
- New and recent drug launches will compensate for biosimilar and generic erosion of current leading brands.
- For most FL patients, both in localized stage and bulky stage, combinations featuring Rituxan are among the most common regimens prescribed.
- Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
- Rituxan's dominance in the market faces threats from upcoming biosimilar competition and from the third-generation monoclonal antibody Gazyva.
- Late-stage drugs in development potentially satisfy the need for more second-line Rituxan-refractory follicular lymphoma therapies.
Key Topics Covered
- Forecast: Follicular Lymphoma
- Treatment: Follicular Lymphoma
- Epidemiology: Follicular Lymphoma
- Marketed Drugs: Follicular Lymphoma
- Pipeline: Follicular Lymphoma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/q2qlvk/nhl_follicular?w=4